Lecanemab: A hope in the management of Alzheimer's disease.
作者信息
Thakkar Nandita, Martis Preetham Basil, Kutikuppala L V Simhachalam, Kuchana Sai Kiran, Mohapatra Ranjan K
机构信息
Department of General Medicine, Mahatma Gandhi Missions Institute of Health Sciences, Navi Mumbai, Maharashtra, India.
Department of General Medicine, Father Mullers Medical College, Mangalore, Karnataka, India.
出版信息
Brain Circ. 2023 Sep 27;9(3):194-195. doi: 10.4103/bc.bc_10_23. eCollection 2023 Jul-Sep.
Abstract
摘要
相似文献
1
Lecanemab: A hope in the management of Alzheimer's disease.乐卡奈单抗：阿尔茨海默病治疗中的一线希望。
Brain Circ. 2023 Sep 27;9(3):194-195. doi: 10.4103/bc.bc_10_23. eCollection 2023 Jul-Sep.
2
Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.新型抗淀粉样蛋白-β（Aβ）单克隆抗体 Lecanemab 治疗阿尔茨海默病的系统评价。
Int J Immunopathol Pharmacol. 2023 Jan-Dec;37:3946320231209839. doi: 10.1177/03946320231209839.
3
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
A Path to Improved Alzheimer's Care: Simulating Long-Term Health Outcomes of Lecanemab in Early Alzheimer's Disease from the CLARITY AD Trial.改善阿尔茨海默病护理的途径：从CLARITY AD试验模拟lecanemab在早期阿尔茨海默病中的长期健康结局
Neurol Ther. 2023 Jun;12(3):863-881. doi: 10.1007/s40120-023-00473-w. Epub 2023 Apr 2.
5
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.预测日本早期阿尔茨海默病中lecanemab的社会价值：一项患者层面的模拟研究
Neurol Ther. 2023 Aug;12(4):1133-1157. doi: 10.1007/s40120-023-00492-7. Epub 2023 May 15.
6
Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease.Lecanemab Clarity AD：早期阿尔茨海默病的一项随机、双盲 3 期临床试验的生活质量结果。
J Prev Alzheimers Dis. 2023;10(4):771-777. doi: 10.14283/jpad.2023.123.
7
Estimated Societal Value of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.使用模拟模型评估早期阿尔茨海默病患者中lecanemab的社会价值。
Neurol Ther. 2023 Jun;12(3):795-814. doi: 10.1007/s40120-023-00460-1. Epub 2023 Mar 16.
8
Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer's Disease Using Simulation Modeling.使用模拟模型评估lecanemab对早期阿尔茨海默病患者的长期健康结局
Neurol Ther. 2022 Jun;11(2):863-880. doi: 10.1007/s40120-022-00350-y. Epub 2022 Apr 25.
9
Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.仑卡奈单抗治疗阿尔茨海默病的安全性和有效性：随机临床试验的系统评价和荟萃分析
Front Aging Neurosci. 2023 May 5;15:1169499. doi: 10.3389/fnagi.2023.1169499. eCollection 2023.
10
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.利斯的明透皮贴剂（Leqembi）并不适合阿尔茨海默病患者。
Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.
引用本文的文献
1
Evaluating the safety and feasibility of remote ischemic conditioning for slowing cognitive decline in mild Alzheimer's dementia.评估远程缺血预处理对减缓轻度阿尔茨海默病性痴呆认知衰退的安全性和可行性。
Front Neurol. 2025 Jun 24;16:1592829. doi: 10.3389/fneur.2025.1592829. eCollection 2025.
2
Mitochondrial unfolded protein response (UPR) as novel therapeutic targets for neurological disorders.线粒体未折叠蛋白反应（UPR）作为神经系统疾病的新型治疗靶点。
J Cereb Blood Flow Metab. 2025 May 15:271678X251341293. doi: 10.1177/0271678X251341293.
3
From genes to drugs: targeting Alzheimer's with circadian insights.从基因到药物：利用昼夜节律洞察来靶向治疗阿尔茨海默病
Front Aging Neurosci. 2025 Mar 26;17:1527636. doi: 10.3389/fnagi.2025.1527636. eCollection 2025.
4
Expression of SARS-CoV-2 entry receptor ACE2 in human brain and its association with Alzheimer's disease and COVID-19.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进入受体血管紧张素转换酶2（ACE2）在人脑中的表达及其与阿尔茨海默病和2019冠状病毒病（COVID-19）的关联
Mol Psychiatry. 2025 Apr 6. doi: 10.1038/s41380-025-03006-z.
5
From Mechanisms to Medicine: Neurovascular Coupling in the Diagnosis and Treatment of Cerebrovascular Disorders: A Narrative Review.从机制到医学：脑血管疾病诊断与治疗中的神经血管耦合：一篇综述
Cells. 2024 Dec 27;14(1):16. doi: 10.3390/cells14010016.
6
Exosomes in Central Nervous System Diseases: A Comprehensive Review of Emerging Research and Clinical Frontiers.中枢神经系统疾病中的外泌体：新兴研究与临床前沿的综合综述
Biomolecules. 2024 Nov 27;14(12):1519. doi: 10.3390/biom14121519.
7
Causal relationships between dyslexia and the risk of eight dementias.阅读障碍与八种痴呆症风险之间的因果关系。
Transl Psychiatry. 2024 Sep 12;14(1):371. doi: 10.1038/s41398-024-03082-9.
本文引用的文献
1
Accelerated Brain Volume Loss Caused by Anti-β-Amyloid Drugs: A Systematic Review and Meta-analysis.抗β-淀粉样蛋白药物导致的脑容量加速丢失：系统评价和荟萃分析。
Neurology. 2023 May 16;100(20):e2114-e2124. doi: 10.1212/WNL.0000000000207156. Epub 2023 Mar 27.
2
Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.阿尔茨海默病：尽管存在成本和安全方面的担忧，美国食品药品监督管理局仍批准了仑卡奈单抗。
BMJ. 2023 Jan 11;380:73. doi: 10.1136/bmj.p73.
3
FDA approves Alzheimer's drug lecanemab amid safety concerns.尽管存在安全担忧，美国食品药品监督管理局仍批准了治疗阿尔茨海默病的药物lecanemab。
Nature. 2023 Jan;613(7943):227-228. doi: 10.1038/d41586-023-00030-3.
4
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
5
Impact of interventions to reduce Alzheimer's disease pathology on the prevalence of dementia in the oldest-old.减少阿尔茨海默病病理改变的干预措施对高龄老人痴呆症患病率的影响。
Alzheimers Dement. 2016 Mar;12(3):225-32. doi: 10.1016/j.jalz.2016.01.004. Epub 2016 Feb 17.
Zotero 插件